The two next-generation ADC drugs following ‘Enhertu’ draw attention as they are currently being considered reimbursement listing in South Korea.

Gilead Science Korea’s Trodelvy (Sacituzumab govitecan), used to treat triple-negative breast cancer (TNBC), and Astellas Pharma Korea’s Padcev (enfortumab vedotin), used to treat bladder cancer, have cleared the Cancer Disease Review Committee of the Health Insurance Review and Assessment Service (HIRA). The drugs are now being considered for follow-up discussions in the Economic Evaluation Committee.

The two drugs are known as antibody-drug conjugates (ADCs) and have demonstrated improved benefits compared to existing therapies in